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Objective: Glucocorticoids (GC) are associated with side effects in giant cell arteritis (GCA). Immunosuppressive
therapies (ITs) have given conflicting results in GCA, regarding GC sparing effect. Primary endpoint is to evaluate
whether very early introduction of ITs in GCA minimize the rate of GC-induced adverse events, in terms of in-
fections, new onset systemic arterial hypertension, GC-induced diabetes and osteoporotic fractures.
Methods: A multicenter retrospective case-control study included 165 patients. One group included 114 patients
who were treated with at least one IT given at diagnosis or within 3 months from the start of GC. A second group
included 51 GCA who received only GC or an IT more than 3 months later.
Results: The most frequently used ITs were: methotrexate (138 patients), cyclophosphamide (48 patients) and
tocilizumab (27 patients). No difference was observed as concerns the follow-up time between groups [48.5 (IQR
26–72) vs 40 (IQR 24–69), p ¼ 0.3)]. The first group showed a significantly lower incidence of steroid-induced
diabetes (8/114, 7% vs 12/51, 23.5%; p ¼ 0.003) and no differences for the rate of infections (p ¼ 0.64). The
group was also exposed to lower doses of GC at first (p < 0.0001) and third (p < 0.0001, rank-sum test) month.
Forty-four patients in the first group (38.6%) compared with 34 in the second one (66.7%) experienced at least
one relapse (p ¼ 0.001).
Conclusion: Very early introduction of IT in GCA lowered the incidence of steroid-induced diabetes, possibly due
to the lower doses of GC in the first three months. Relapse rate was even lower.1. Introduction
Giant cell arteritis (GCA) is the most common form of primary
vasculitis [1–3]. It is a granulomatous inflammation of medium to
large-sized vessels, mainly affecting cranial branches of arteries origi-
nating from the aortic arch, including the temporal arteries, with
potentially disabling complications. Large artery complications are also.it (L. Quartuccio).
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evier B.V. This is an open accessincreasingly well recognized [1,2,4]. Glucocorticoids (GC) remain the
mainstay of treatment of GCA and guidelines usually recommend an
initial prednisone dosage of 40–60 mg/day gradually tapered over a
period of 1–2 years [5]. This strategy is usually effective in controlling
the disease and preventing progressive blindness. However, relapses
occur in up to 50% of patients when GC are tapered and prolonged
courses of GC are associated with serious side effects, which greatly affect16 November 2020
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Table 1
Demographic, clinical, laboratory, instrumental and histological features of the
GCA-IT and GCA-control groups.






Age at diagnosis, mean (SD) 68.9 (7.7) 72.3 (7.1) 0.005
Female, n (%) 84 (73.7) 43 (84.3) 0.134
1990 ACR Classification criteria,
median (IQR)
3 (2–4) 4 (3–5) 0.005
Headache, n (%) 79 (69.3) 42 (82.3) 0.080
Jaw claudication, n (%) 40 (35.4) 28 (54.9) 0.019
Temporal artery abnormalities 48/114 (42.1) 30/51 (58.8) 0.047
PMR, n (%) 56 (49.6) 28 (54.9) 0.526
Fever, n (%) 50 (44.2) 23 (45.1) 0.919
Visual impairment, n (%) 22 (19.5) 16 (31.4) 0.094
Extracranial clinical involvement,
n (%)
68 (59.6) 26 (51) 0.299
Ischemic complications (cranial
and/or extracranial)
247,114 (21.1) 5/46 (9.8) 0.079
ESR, mm/h, mean (SD) 74 (30.6) 81.6 (25.4) 0.135
CRP, mg/l, median (IQR) 48 (14.3–96.1) 64.5
(37.25–105.25)
0.033
Positive PET-CT, n/N (%) 46/53 (86.8) 12/16 (75) 0.259
Positive temporal artery biopsy,
n/N (%)
40/96 (41.7) 22/45 (48.9) 0.421
Follow-up, months, median (IQR) 48.5 (26–72) 40 (24–69) 0.304
Legend: SD, standard deviation; PMR, polymyalgia rheumatica; ESR, erythrocyte
sedimentation rate; CRP, C-Reactive Protein; PET-CT, Positron emission tomog-
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effectiveness of a GC-sparing immunosuppressive therapy (IT), yielding
conflicting results. To date, three randomized controlled trials have
evaluated the use of methotrexate in patients with newly diagnosed GCA,
with two of them showing no steroid-sparing benefit [7–9]. A subsequent
meta-analysis showed a modest benefit of methotrexate, with fewer re-
lapses and lower GC exposure in patients on methotrexate [10]. Un-
controlled retrospective case reports and case series also reported the
beneficial effects of cyclophosphamide, although burdened with possible
serious adverse events (AEs) [11–14]. Tocilizumab, a humanized
monoclonal antibody directed against the IL-6 receptor, has been
licensed for GCA, based on the results of a phase 2 trial and a large,
multicenter, phase 3 randomized controlled trial [15,16]. Nevertheless,
tocilizumabmay have some limitations since it is an expensive drug, with
some contraindications. On the other hand, still limited information is
available regarding long-term outcome and steroid sparing effect of other
ITs in GCA, while they may be of value as further options to improve the
outcome of GCA patients.
2. Materials and methods
We retrospectively enrolled 165 patients with follow up details of at
least one year from the departments of internal medicine and rheuma-
tology at four tertiary hospitals located in Udine, Roma, Pisa and Flor-
ence. All patients were diagnosed with GCA between 2007 and 2016
based on the presence of at least 3 criteria of the American College of
Rheumatology (ACR) [17] or demonstration of large vessel involvement
on imaging. For the purpose of this study, we enrolled consecutive pa-
tients with GCA who received an adjunctive IT given very early after GCA
diagnosis, i.e. ab initio or within 3 months from the start of GC (GCA-IT).
These groups were compared with consecutive patients with GCA who
never received an adjunctive IT or IT was given later than 3 months after
GCA diagnosis (GCA-control). The data were collected in a retrospective
manner from our institutions’ electronic medical records. The following
were included in a standardized form: demographics, clinical manifes-
tations and laboratory tests [including C-Reactive Protein (CRP), eryth-
rocyte sedimentation rate (ESR)] at diagnosis and lastly follow up visit
and temporal artery biopsy status when available. We also retrieved the
dose of GC at treatment initiation and at months 3, 6, 12, 24 and 48, if
ongoing, the number of disease relapse events, as well as the occurrence
of the most commonly reported complications of GC, i.e. infectious
events, new onset or deterioration of systemic arterial hypertension,
steroid-induced diabetes (new or worsening of a pre-existing type 2
diabetes) and new fragility fractures. Remission was defined as the
absence of symptoms or signs, along with ESR <40 mm/h or CRP <10
mg/l. Relapse was defined in the presence of either one of the signs and
symptoms that newly appeared or worsened after achieving clinical
remission. Given the retrospective nature of the study, no medical ther-
apy protocol was adopted. The choice of IT was made by the treating
physician according to his/her judgement of disease activity and patient
comorbidity. Similarly, the initial GC dosage, as well as lower subsequent
dosages, were based on the physician’s decision. Most patients received
more than one IT during the follow-up, as this was modified in case of
insufficient response or intolerance. The decision to give an immuno-
suppressant along with steroid therapy was made regardless of the
severity of manifestations or presence of pre-existing comorbidities.
Usually, the treatment strategy includedmethotrexate as first therapeutic
choice, except for contraindications or very high disease activity. In the
latter case, it was preferred to use cyclophosphamide (intravenous or
orally) or tocilizumab intravenously or subcutaneously, when available.
Informed consent to use clinical data was obtained from all individual
participants included in the study. The study was conducted in accor-
dance with the ethical principles of the Helsinki Declaration (WMA,
2013).2
2.1. Statistical analysis
Descriptive statistics summarized data using the mean and standard
deviation or median and interquartile range (IQR), as appropriate based
on the variable distribution, or even frequencies for dichotomic vari-
ables; consequently, comparisons between GCA-IT and GCA-control
groups were made by parametric (t-test for two independent samples)
or no parametric tests (Mann-Whitney test) for continuous variable,
while chi square tests for dichotomic variables. The log rank test was
used to test the null hypothesis that there was no difference between
GCA-IT and GCA-control groups in the probability of relapse as event, at
any time point.
3. Results
3.1. Demographic and clinical features at onset
Overall, methotrexate up to 20 mg/week was employed in 138/165
(83.6%) patients, cyclophosphamide givenmonthly at the dose of 15mg/
kg intravenously adjusted for age and renal function, or given orally at
the dose of 1.5–2 mg/kg/day for three months in 48/165 (29%) patients
and tocilizumab either intravenously at the dose of 8 mg/kg per month or
162 mg weekly subcutaneously in 27/165 (16.4%) patients. GCA-IT
group comprised 114 patients, while 51 patients belonged to GCA-
control group. Characteristics of the two groups are reported in
Table 1. Notably, there were no differences regarding sex distribution (p
¼ 0.134), while GCA-IT group patients were significantly younger than
GCA-control patients (p ¼ 0.009, two-sample Wilcoxon rank-sum test-
Mann-Whitney test), even if the mean age of each group was over 65
years. At least three classification criteria were satisfied by 81/114 vs 48/
51 patients, respectively in GCA-IT and GCA-control group (p ¼ 0.002).
No difference was noticed in the number of patients who had undergone
temporal artery biopsy (96/114 vs 45/51, p ¼ 0.195), as well as in the
rate of positive results from biopsy (40/96 vs 22/45, p ¼ 0.421). Yet, at
onset, statistically significant differences between groups were recorded
in the rate of temporal artery abnormalities (48/114 vs 30/51, p ¼
0.047), and masticatory claudication (40/113 vs 28/51, p ¼ 0.019), but
not headache, visual impairment, and extracranial manifestations,raphy–computed tomography; CTA, computed tomography angiography; MRA,
magnetic resonance angiography; IQR, interquartile range 25%–75%.
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both cranial and extracranial ischemic complications appeared more
frequent in the first group (Table 1). Start prednisone dosage was not
statistically different between groups (p ¼ 0.066). Treatments employed
in the GCA-IT group are described in Table 2. Time of observation was
not statistically different between GCA-IT and GCA-control groups (p ¼
0.304). Pre-existing comorbidity did not appear different between groups
(table S1).
3.2. Outcomes
3.2.1. Primary outcome: GC-related complications
During the whole follow-up, the number of infectious complications
was not statistically different between groups (19/114 vs 10/51, p ¼
0.646, Pearson chi square test), even for those requiring hospitalization
(5/19 vs 1/10, p ¼ 0.583, Pearson chi square test). Importantly, the rate
of steroid-induced diabetes was significantly lower in the GCA-IT group
(8/114 vs 12/51, p ¼ 0.003). The number of patients with new onset or
worsening arterial systemic hypertension was not different (11/114 vs 6/
51, p ¼ 0.680, Pearson chi square test), as well as for the rate of new
fragility fractures (15/114 vs 4/51, p ¼ 0.323, Pearson chi square test).
3.2.2. Secondary outcomes: steroid sparing, relapse rate, adverse events
The ongoing prednisone dose at the end of the first month, as well as
at the end of the third month, was significantly lower in the GCA-IT group
[36.25 mg/day (IQR 20–50) vs 50 mg/day (IQR 50–62.5); 12.5 mg/day
(IQR 6.25–25) vs 25 mg/day (IQR 12.5–37.5), respectively, p < 0.0001,
two-sample Wilcoxon rank-sum test-Mann-Whitney test in both ana-
lyses], while no differences were observed in the prednisone daily dose
between groups at the end of the sixth [6.25 mg/day (IQR 5–10) vs 6.25
mg/day (IQR 5–10), p ¼ 0.401, two-sample Wilcoxon rank-sum test-
Mann-Whitney test] and twelve month [5 mg/day, IQR (5–6.25) vs 5
(IQR 3.75–5), p ¼ 0.069, two-sample Wilcoxon rank-sum test-Mann-
Whitney test].
The number of patients showing at least one relapse was significantly
lower in GCA-IT group than the GCA-control group (44/114 vs 34/51, p
¼ 0.001), while the number of patients with more than one relapse was
not different among them (9/44 vs 8/34, p ¼ 0.960, Pearson chi squareTable 2
Treatments employed in the two groups and outcomes.




GC alone for the whole follow-upa, n (%) 0 19/51 (37.2)
Methotrexate, n (%) 105 (92.1) 33 (64.7)
Cyclophosphamide, n (%) 39 (34.2) 9 (17.6)
Tocilizumab, n (%) 20 (17.5) 7 (13.7)
Prednisone at onset, median (IQR) 50 (40–62.5) 50 (50–62.5)










Prednisone at the end of sixth month, median
(IQR)
6.25 (5–10) 6.25 (5–10)
Prednisone at the end of twelfth month,
median (IQR)
5 (3.75–5) 5 (5–6.25)
Prednisone at the end of twenty-fourth
month, median (IQR)#
5 (0–5) 2.5 (0–5)
Prednisone at the end of forty-eighth month,
median (IQR)x
1.75 (0–5) 0 (0–5)
Diabetes (%) 8/114 (7) 12/51 (23.5)
Infections (%) 19/114 (16.7) 10/51 (19.6)
Hypertension (%) 11/114 (9.6) 6/51 (11.7)
Fragility fractures (%) 15/114 (13.1) 4/51 (7.8)
a GCA-control group could be treated with IT after at least of three months of
GC alone therapy.
b p value< 0.0001; p value< 0.01; #data available in 150 (103 in GCA-IT, 47
in GCA-control) patients; xdata available in 117 (78 in GCA-IT, 39 in GCA-
control) patients.
3
test). There was no difference in terms of time to first relapse between the
two groups [360 days (150–1081) vs 180 days (90–510), p ¼ 0.144, log-
rank test). Importantly, time (months) to reach 5 mg/day of prednisone
was significantly lower in the GCA-IT group [6 (4–12) vs 9 (6–12), p ¼
0.016)].
The total number of adverse events was not significantly different
between the two groups (51/114 vs 29/51, p¼ 0.203). Among them, the
number of patients with more than one adverse event was again not
statistically different (8/51 vs 7/29, p ¼ 0.527). Adverse events other
than infections secondary to the IT in the GCA-IT group are reported in
Table 3.
4. Discussion
To the best of our knowledge, the current study constitutes the largest
case-control study of GCA comparing a strategy with an upfront use of
steroid sparing ITs from the beginning or very early from the diagnosis
with the standard of care, i.e. GC alone. The time of observation of more
than three years in the majority of the patients was long enough to
evaluate critical clinical outcome in this disease. Our proposed approach
was effective in significantly decreasing the rate of steroid-induced dia-
betes, while not increasing the rate of infections, including the most
serious ones requiring hospitalization, which was recorded at low rate in
both groups, if compared to a previous work (18). Notably, the metho-
trexate arm of Mahr’s study reported an infection rate very close to that
documented in the GCA-control arm of our study, i.e. 20% (10), where
the introduction of IT was delayed. This important result was likely
related to the steroid sparing effect that was clearly seen in our study at
the end of the first and the third month, when the ongoing GC dose was
significantly lower in GCA-IT group than in controls. Recently, Matthew
J. Koster et al. reported a retrospective analysis in 83 GCA patients,
treated with methotrexate and compared with a control group, which
was managed only with GC. The median time to start methotrexate was
39 weeks, i.e. more than 9 months. The rate of relapses significantly
decreased in the MTX group, but the GC reduction was not different
between the two groups, while the cumulative steroid dose was signifi-
cantly higher in the methotrexate group than in the control group [19].
This was justified by the fact that patients taking methotrexate showed a
more severe disease before methotrexate initiation, 24 patients (29%)
had not yet experienced a relapse, while, at index date, 59 (71%) patients
receiving only GC had not yet experienced a relapse. Thus, in this clinical
scenario and in the absence of biomarkers of severity for GCA at the time
of diagnosis, only the very early introduction of IT may produce a clin-
ically significant change in the outcome in GCA, regardless of the severity
of the disease. The absence of difference between the groups regarding
the rate of fragility fractures may be due to the large use of bisphosph-
onates along with calcium and vitamin D supplementation as bone pro-
tection prophylactic treatment, usually employed in this setting. Notably,
despite the more rapid deescalating steroid schedule in GCA-IT group,
the relapses remained significantly lower in that group than in
GCA-control group, and it was even lower than that reported by a recent
meta-analysis [20], thus underlying the early synergic immunosuppres-
sive effect of IT with GC, starting from the first month, when the dosage
of immunosuppressive therapies is appropriate. In fact, while the rapid
effect of cyclophosphamide or tocilizumab is known, for methotrexate,
reaching the maximum well-tolerated dosage, i.e. up to 20 mg/week
within the first two weeks is critical. Mahr et al. performed a
meta-analysis based on data from the three randomized controlled trials
[7–9] which evaluated the use of methotrexate with conflicting results.
The meta-analysis compared two arms of treatment, the first one treated
with methotrexate and prednisolone, the second one including 77 pa-
tients treated with placebo and prednisolone [10]. Moreover, if
compared to the placebo arm, methotrexate produced a significantly
better outcome only after 24 weeks [10]. Since patients in the metho-
trexate group were not more severe than those in the placebo group, it
may be hypothesized that the dosage of methotrexate could be really
Table 3
Adverse events other than infections ascribed to immunosuppressors (as clinical judgement) in GCA-IT group.
Therapy N patients Adverse events Grade Therapy modification Outcome
Methotrexate, n ¼ 35 1 Hypertransaminasaemia 1 None Resolved
1 Hypertransaminasaemia 1 Dose reduction Resolved
7 Hypertransaminasaemia 2 Stop Resolved
3 Nausea 1 None Resolved
4 Nausea 1 Dose reduction Resolved
5 Nausea 1 Stop Resolved
1 Neutropenia 2 Dose reduction Resolved
1 Malaise 1 None Resolved
1 Malaise 1 Dose reduction Resolved
3 Malaise 1 Stop Resolved
1 Oral mucositis 2 Stop Resolved
1 Oral mucositis 1 Dose reduction Resolved
1 Stomatitis 1 Stop Resolved
2 Anaemia 2 Stop Resolved
1 Alopecia 1 Stop Resolved
1 Skin rash 1 Stop Resolved
1 Diarrhoea 1 Stop Resolved
Cyclophosphamide, n ¼ 8 1 Hypertransaminasaemia 2 Stop Resolved
2 Haemorrhagic cystitis 1 None Resolved
1 Hypogammaglobulinemia 1 None Resolved
1 Thrombocytopenia 1 Dose reduction Resolved
1 Laryngeal cancer 3 Stop Persisted
1 Oral mycosis 1 Stop Resolved
1 Abdominal pain 1 Stop Resolved
Tocilizumab, n ¼ 6 2 Thrombocytopenia 1 Dose reduction Resolved
1 Urticarial rash 1 Dose reduction Resolved
1 Leukopenia and thrombocytopenia 2 Stop Resolved
1 Thrombocytopenia and hypogammaglobulinemia 1 None Resolved
1 Neutropenia 1 None Resolved
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tered at a maximum dosage ranging between 7.5 mg/week and 15
mg/week, except in 1 patient whose dosage of methotrexate was grad-
ually increased to 17.5 mg/week [10]. Thus, this analysis further sup-
ports the effectiveness of methotrexate at higher dosage in reducing
relapses if compared with GC alone. Mahr et al. have already demon-
strated in their meta-analysis that treatment with methotrexate
decreased the cumulative exposure to GC [10], while they did not
recommend a more rapid steroid tapering regimen, due to the possible
delayed effect of adjunctive IT [10], which is expected at those lower
dosages.
With regard to cyclophosphamide, current evidence on its role in GCA
is scarce and limited to retrospective studies and case reports, including a
retrospective study conducted by our group [11], where it appears to be
effective in reducing steroid use within the first 6 months. In our study, it
appears that cyclophosphamide was chosen for patients showing a more
aggressive disease, in particular for those with ischemic complications
and/or extracranial, large vessel involvement (Table 1). Interestingly,
large vessel involvement at diagnosis has been recently associated with
reduced survival in GCA [21], and, therefore, it may justify the choice of
a deeper immunosuppression. Conversely, efficacy of tocilizumab in
reducing GC exposure was assessed and clearly demonstrated by several
studies, and above all by the GiACTA trial [16], which led to the
authorization of its commercial use in GCA. Nevertheless, no study,
including Mahr’s meta-analysis [10] before ours, has so far demonstrated
a reduction in the rate of adverse events secondary to GC therapy.
Globally, all other series were characterized by a significantly lower use
of IT [6,10,18,22,23]. This outcome probably requires a long-term fol-
low-up and, more importantly, not only new drugs, but also a new
treatment algorithm, including early (within the first three month)
introduction of an IT and a treat-to-target strategy. Nevertheless, some
patients experienced adverse events, usually grade 1 or 2, secondary to
IT, which, however, led to therapy withdrawal only in 14/114 (12.3%).
Anyway, in all these cases an alternative IT was successfully started, and
well tolerated. Our study has several limitations. First, the retrospective
design limited the completeness of the retrieved data, especially the
follow-up data. In addition, the treatment was not standardized and both4
initial dose and tapering regimens were at the discretion of the treating
physician, although all the recruiting centres usually adopted a similar
GC schedule in order to minimize the GC exposure in their own patients.
Randomized controlled trial or observational prospective cohort study
with the aim to determine long-term outcome using uniform treatment
protocol would be needed and it has been recently claimed for metho-
trexate [24]. Further, patients undergoing IT were slightly younger from
a statistical point of view, though it was not clinically relevant in our
opinion. Otherwise, younger age may be a safety reason for the clinician
to introduce IT in GCA early. Indeed, the 1990 ACR classification criteria
for GCA were lesser satisfied by patients belonging to GCA-IT group than
controls. In the former, typical specific cranial involvement and a positive
temporal artery biopsy were less frequent, whereas they tended to show
predominantly extra-cranial manifestations. This data definitely reflects
the characteristics of real-life patients with GCA and underlines the
limited sensitivity of the current classification criteria, especially in those
patients with large vessel involvement. Similarly, the GiACTA trial
enrolled 46% patients diagnosed with GCA based on imaging [16].
Provisional new classification criteria for GCA appear to have definitely
incorporated this concept [25].
5. Conclusion
This study suggests that a very early introduction of IT, i.e. within the
third month from diagnosis, could be a valid therapeutic strategy, espe-
cially in a population in which GC use must be minimized [26]. This
strategy, in our study, was definitely effective in decreasing GC-related
adverse effects in the long term, by lowering the exposure to GC early
and reducing the risk of relapse. This is the main objective of treatment in
GCA, which is the most frequent primary vasculitis in the adults, and it
often affects elderly patients [27]. The choice of the type of immuno-
suppressant should be individualized based on the severity of the man-
ifestations, comorbidity, contraindications, and, finally, on the available
resources [28]. At present, comorbidity such as hypertension, venous
thrombosis or diabetes at diagnosis, or systemic or local signs of much
more inflamed disease (i.e. fever, anaemia or histological signs of more
active disease) may predict relapse in GCA [18,29,30], which is much
L. Quartuccio et al. Journal of Translational Autoimmunity 3 (2020) 100072more frequent in the first year of treatment [20]. Indeed, no valid bio-
markers have been found to predict which patients are at most risk for
developing GC resistance in GCA [31]. Further prospective studies are
needed to confirm these findings and try to personalize treatment strat-
egy in each patient.
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